Skip to main content

Table 4 Changes from baseline in secondary efficacy endpoints over Weeks 1–24 (intent-to-treat population)

From: Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

  FF 100 μg FF 200 μg
  (N = 108) (N = 111)
Percentage of rescue-free 24-hour periods (Weeks 1–24)
n 108 109
Baseline 14.3 11.5
LS mean change from baseline (SE) 21.3 (3.05) 23.1 (3.03)
Treatment difference vs. FF 100 μg (95% CI) NA 1.8
   (-6.7, 10.3)
Percentage of symptom-free 24-hour periods (Weeks 1–24)
n 108 109
Baseline 6.1 4.9
LS mean change from baseline (SE) 17.5 (2.80) 19.6 (2.79)
Treatment difference vs. FF 100 μg (95% CI) NA 2.1
   (-5.7, 9.9)
PM peak expiratory flow (L/min) (Weeks 1–24)
n 108 109
LS mean 342.7 344.0
LS mean change from baseline (SE) 5.9 (3.26) 7.2 (3.25)
Treatment difference vs. FF 100 μg (95% CI) NA 1.3
   (-7.8, 10.4)
AM peak expiratory flow (L/min) (Weeks 1–24)
n 108 109
LS mean 340.8 340.6
LS mean change from baseline (SE) 13.4 (3.22) 13.2 (3.20)
Treatment difference vs. FF 100 μg (95% CI) NA -0.2
   (-9.2, 8.8)
  1. Note: analysis performed using ANCOVA with covariates of baseline, region, sex, age and treatment.
  2. CI = confidence interval; FF = fluticasone furoate; LS = least squares; NA = not applicable; SE = standard error.